Case 5: New Clinical Trials in Renal Transplantation

Transplantation

Volumn 76, Issue 8, 2003, Pages 1270-1274

  Hariharan, Sundaram ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; HEPATITIS; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; MORBIDITY; MORTALITY; PARVOVIRUS; PATIENT MONITORING; POLYOMA VIRUS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADULT; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HEPATITIS B; HEPATITIS C; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; POLYOMAVIRUS INFECTIONS; VIRUS DISEASES;

EID: 0242300595     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001; 12: 848-55.
2. Tolkoff-Rubin N, Rubin RH. The impact of cytomegalovirus infection on graft function and patient outcome. Graft 1999; 2(suppl 2): S101-33.
3. Babel N, Kern F, Volk HD, et al. Cytomegalovirus infections in kidney transplant patients. Transplantation Reviews 2002; 16: 121-30.
4. Smith SR, Butterly DW, Alexander BD, et al. Viral infections after renal transplantation. Am J Kidney Dis 2001; 37: 659-76.
5. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13: 83-121.
6. Ram Peddi V, Hariharan S, Schroeder TJ, et al. Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts. Nephron 1997; 76: 49-55.
7. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118-25.
8. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35: 866-72.
9. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-6.
10. Baliga R, Schold J, Kaplan B, et al. CMV matching is associated with significantly better graft survival: a paired kidney analysis [abstract 573]. Am J Transplant 2003; 3(suppl 5): 298.
11. Howell DN, Smith SR, Butterly DW, et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999; 68: 1279-88.
12. Randhawa PS, Demetris AJ. Nephropathy due to polyomavirus type BK. N Engl J Med 2000; 342: 1361-3.
13. Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15: 324-32.
14. Mylonakis E, Goes N, Rubin RH, et al. BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation 2001; 72: 1587-92.
15. Boubenider S, Hiesse C, Marchand S, et al. Post-transplantation polyomavirus infections. J Nephrol 1999; 12: 24-9.
16. Ahuja M, Cohen EP, Dayer AM, et al. Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis. Transplantation 2001; 71: 896-9.
17. Ahsan N, Shah KV. Polyomaviruses: an overview. Graft 2002; 5(suppl): S9-S18.
18. Roskopf J, Fitzsimmons W, Ahsan N, et al. The pharmacologic treatment of human polyomavirus infection. Graft 2002; 5(suppl): S88-S97.
19. Kadambi PV, Josephson MA, Williams J, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003; 3: 186-91.
20. Vats A, Shapiro R, Randhawa PS, et al. BK virus associated nephropathy and cidofovir: long term experience. Am J Transplant 2003; 3(suppl 5): 190.
21. Poduval RD, Kadambi PV, Javaid B, et al. Leflunomide - a potential new therapeutic agent for BK nephropathy. Am J Transplant 2003; 3(suppl 5): 189.
22. Foster P, Wright F, McLean D, et al. Leflunomide administration as an adjunct in treatment of BK-polyoma viral disease in kidney allografts. Am J Transplant 2003; 3(suppl 5): 421.
23. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145-51.
24. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11(suppl 15): S1-86.
25. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427-37.
26. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843-61.
27. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63.
28. Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62: 297-9.
29. Rao KV, Anderson WR, Kasiske BL, et al. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993; 94: 241-50.
30. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53: 1374-81.
31. Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29: 608-14.
32. Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167: 630-3.
33. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplant Proc 1998; 30: 3270-2.
34. Izopet J, Rostaing L, Sandres K, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181: 852-8.
35. Mahmoud IM, Sobh MA, Am GM, et al. A prospective study of hepatitis C viremia in renal allograft recipients. Am J Nephrol 1999; 19: 576-85.
36. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30.
37. Zervos XA, Weppler D, Fragulidis GP, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998; 65: 1044-6.
38. Telegdy L, Gorog D, Horanyi M, et al. Severe relapse of hepatitis C following liver transplantation. Successful treatment with a combination of interferon-alpha and ribavirin. Orv Hetil 1999; 140: 1891-3.
39. Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 1912-4.